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Impact of negative methicillin-resistant Staphylococcus aureus (MRSA)
nasal swab on total duration of MRSA therapy for pneumonia patients
Darren Yum PharmD; Danielle Gagne PharmD; Heather Ellis PharmD; Kayihura Manigaba PharmD, BCIDP
North Florida Regional Medical Center (NFRMC), Gainesville, FL
Background
• It is estimated that up to 50% of antimicrobials prescribed in the acute
care settings are either inappropriate or unnecessary.1
• Despite low prevalence of MRSA in community acquired pneumonia,
empiric antibiotic regimens sometimes include coverage of MRSA with an
agent such as vancomycin, and it can be difficult to narrow coverage in a
timely manner, or even at all, as sputum cultures are not usually
available.2
• One study reported the prevalence of MRSA in community acquired
pneumonia to be 0.6%.3
• Based on HCA data from 2014-2017, the incidence of MRSA pneumonia was
estimated to be 1.7%, indicating the majority of patients with pneumonia
do not need anti-MRSA therapy.
• Nasal screening for MRSA has been shown to have a high negative
predictive value (>94%) across different types of pneumonia.4

Methodology
• Retrospective cohort study exempted from the Institutional Review Board.
• The Wilcoxon Signed Rank Test will be used to measure continuous data while the Chi
Square or Fisher’s Exact Test will be used to measure categorical data.

Inclusion Criteria

Exclusion Criteria

Adults 18 years or older

Patients < 18 years old

Clinical diagnosis of pneumonia
based on ICD codes

Nasal swab obtained after 72
hours or more of MRSA therapy

Patients on anti-MRSA therapy
(vancomycin, linezolid,
ceftaroline)

Primary infection other than
respiratory tract infection
Pregnant patients
Prisoners

Data Collection
Demographics
Laboratory

Height, weight, age, sex, race, comorbidities, history of pneumonia,
IV antibiotic use within the previous 90 days
Complete blood count, basic metabolic panel, radiographic imaging

Diagnosis

Pneumonia (all types)

Hospital
Course

Dates of hospital admission and discharge

Other

30 day all-cause mortality

Purpose
This study will assess the impact of negative MRSA nasal swabs on the duration of
anti-MRSA therapy.

Other

• Secondary endpoints:
•
•
•
•

• Study period will take place from July 2018 to July 2019.

• When compared to blood and sputum cultures, MRSA nasal swab offers
quicker turn-around time, and is less affected by preceding anti-MRSA
antibiotic administration as it detects genetic material rather than viable
organisms.7

• Reduction in unnecessary anti-MRSA therapy could save resources by
decreasing both anti-MRSA cost and cost associated with lab monitoring, as
well pharmacist time spent dosing agents such as vancomycin.

• Primary endpoints:
• Anti-MRSA days of therapy

• Recent literature has highlighted MRSA nasal screening as a possible
antimicrobial stewardship program tool to avoid unnecessary empiric MRSA
therapy for pneumonia.5

• Rapid de-escalation from unnecessary anti-MRSA coverage could prevent
patient harm, such as renal toxicity and development of healthcare
acquired infections and resistance.8

Outcome Measures

Cost

Data will be collected using the clinical surveillance platform, Vigilanz, the electronic health
record (EHR) and the computerized physician order entry system, Meditech.

Patient length of stay
Cost to the facility
30 day all-cause mortality
Nephrotoxicity as defined by the KDIGO guidelines ( increase in
serum creatinine > 1.5 times the base line, > 0.3 mg/dL within 48
hours, and Urine volume < 0.5 ml/kg/h for 6 hours.)

Results
Research study in progress, no results available at this time.
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